Cargando…
Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and part...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649290/ https://www.ncbi.nlm.nih.gov/pubmed/37959263 http://dx.doi.org/10.3390/jcm12216798 |
_version_ | 1785135532897992704 |
---|---|
author | Escobar, Carlos Pascual-Figal, Domingo Manzano, Luis Nuñez, Julio Camafort, Miguel |
author_facet | Escobar, Carlos Pascual-Figal, Domingo Manzano, Luis Nuñez, Julio Camafort, Miguel |
author_sort | Escobar, Carlos |
collection | PubMed |
description | Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and particularly, the pooled analysis of both studies, have shown that dapagliflozin significantly reduces the risk of cardiovascular death, all-cause death, total HF hospitalizations, and MACE in the whole spectrum of HF, with sustained benefits over time. Recent data have shown that the full implementation of dapagliflozin in clinical practice would translate into a robust reduction in hospitalizations for HF and death in real-life populations. Many pathophysiological mechanisms have been involved in these benefits, particularly the positive effects of dapagliflozin on reversing cardiac (atrial and ventricular) remodeling, reducing cardiac fibrosis and inflammation, and improving endothelial dysfunction. In this manuscript, we reviewed from a practical point of view the role of dapagliflozin in the management of the whole spectrum of patients with HF. |
format | Online Article Text |
id | pubmed-10649290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106492902023-10-27 Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin Escobar, Carlos Pascual-Figal, Domingo Manzano, Luis Nuñez, Julio Camafort, Miguel J Clin Med Review Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in managing patients with HF, regardless of ejection fraction, to reduce HF burden. The DAPA-HF and DELIVER trials, and particularly, the pooled analysis of both studies, have shown that dapagliflozin significantly reduces the risk of cardiovascular death, all-cause death, total HF hospitalizations, and MACE in the whole spectrum of HF, with sustained benefits over time. Recent data have shown that the full implementation of dapagliflozin in clinical practice would translate into a robust reduction in hospitalizations for HF and death in real-life populations. Many pathophysiological mechanisms have been involved in these benefits, particularly the positive effects of dapagliflozin on reversing cardiac (atrial and ventricular) remodeling, reducing cardiac fibrosis and inflammation, and improving endothelial dysfunction. In this manuscript, we reviewed from a practical point of view the role of dapagliflozin in the management of the whole spectrum of patients with HF. MDPI 2023-10-27 /pmc/articles/PMC10649290/ /pubmed/37959263 http://dx.doi.org/10.3390/jcm12216798 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Escobar, Carlos Pascual-Figal, Domingo Manzano, Luis Nuñez, Julio Camafort, Miguel Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
title | Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
title_full | Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
title_fullStr | Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
title_full_unstemmed | Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
title_short | Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin |
title_sort | current role of slgt2 inhibitors in the management of the whole spectrum of heart failure: focus on dapagliflozin |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649290/ https://www.ncbi.nlm.nih.gov/pubmed/37959263 http://dx.doi.org/10.3390/jcm12216798 |
work_keys_str_mv | AT escobarcarlos currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin AT pascualfigaldomingo currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin AT manzanoluis currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin AT nunezjulio currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin AT camafortmiguel currentroleofslgt2inhibitorsinthemanagementofthewholespectrumofheartfailurefocusondapagliflozin |